Gouty Arthritis (Gout) - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 105
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GA511A3BE1BEN
Leaflet:

Download PDF Leaflet

Gouty Arthritis (Gout) - Pipeline Review, H2 2016
Gouty Arthritis (Gout) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis (Gout) – Pipeline Review, H2 2016, provides an overview of the Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline landscape.

Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis (Gout) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 8, 3, 14, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Gouty Arthritis (Gout).

Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Gouty Arthritis (Gout) Overview
Therapeutics Development
Pipeline Products for Gouty Arthritis (Gout) - Overview
Pipeline Products for Gouty Arthritis (Gout) - Comparative Analysis
Gouty Arthritis (Gout) - Therapeutics under Development by Companies
Gouty Arthritis (Gout) - Therapeutics under Investigation by Universities/Institutes
Gouty Arthritis (Gout) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Gouty Arthritis (Gout) - Products under Development by Companies
Gouty Arthritis (Gout) - Products under Investigation by Universities/Institutes
Gouty Arthritis (Gout) - Companies Involved in Therapeutics Development
Allena Pharmaceuticals, Inc.
AstraZeneca Plc
C&C Research Laboratories
Cell Medica Limited
Immune Response BioPharma, Inc.
IOmet Pharma
Jiangsu Hengrui Medicine Co., Ltd.
LG Life Science LTD.
Monosol Rx LLC
Nimbus Therapeutics, LLC
Opsona Therapeutics Limited
Polaris Pharmaceuticals, Inc.
ProteoThera, Inc.
Selvita S.A.
Swedish Orphan Biovitrum AB
Teijin Pharma Limited
TWi Pharmaceuticals, Inc.
Wellstat Therapeutics Corporation
XL-protein GmbH
Gouty Arthritis (Gout) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALLN-346 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anakinra - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQB-565 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AXIBU-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
colchicine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diacerein - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DLX-2323 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DLX-2681 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
febuxostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IR-888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LC-350189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit S100A9 Protein for Autoimmune Disorders, Chronic Inflammation and Respiratory Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-2110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-2158 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ND-346 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegadricase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRT-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Enzyme for Gout and Tumor Lysis Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REV-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RLBN-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SEL-212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-4640 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule Inflammasome Modulator Programme - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit GLUT9 for Gout - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMX-049 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
URC-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
uriSHELS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
verinurad - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WT-2107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XEN-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XEN-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gouty Arthritis (Gout) - Dormant Projects
Gouty Arthritis (Gout) - Discontinued Products
Gouty Arthritis (Gout) - Product Development Milestones
Featured News & Press Releases
Oct 26, 2016: Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout
Jun 27, 2016: TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment
May 10, 2016: Revive Therapeutics Provides Clinical and Corporate Update
Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra)
Mar 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra)
Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients
Dec 23, 2015: Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout
Oct 19, 2015: MonoSol Rx Leadership Presents Data Supporting PharmFilm Technology Effective for Oral Peptide Delivery
Sep 30, 2015: Revive Therapeutics Announces Positive Interim Results From Phase 2a Study of REV-002 in the Treatment of Acute Gout Flares
Jun 30, 2015: New Indication for Teijin Pharma’s Febuxostat in Europe
Jun 10, 2015: Selecta Biosciences Initiates Phase 1 Clinical Program of SEL-212, Designed As the First Non-Immunogenic Biologic Treatment for Gout
Feb 27, 2015: Stiris Research Awarded a Phase IIa Trial in Gout
Feb 26, 2015: Revive Therapeutics Expands its Orphan Drug Indication Pipeline to Include Cystinuria and Wilson Disease
Dec 12, 2014: TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan
Nov 26, 2014: Revive Therapeutics Announces US FDA Acceptance of IND to Commence Clinical Trial for Bucillamine for the Treatment of Gout
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 105

LIST OF TABLES

Number of Products under Development for Gouty Arthritis (Gout), H2 2016
Number of Products under Development for Gouty Arthritis (Gout) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Gouty Arthritis (Gout) - Pipeline by Allena Pharmaceuticals, Inc., H2 2016
Gouty Arthritis (Gout) - Pipeline by AstraZeneca Plc, H2 2016
Gouty Arthritis (Gout) - Pipeline by C&C Research Laboratories, H2 2016
Gouty Arthritis (Gout) - Pipeline by Cell Medica Limited, H2 2016
Gouty Arthritis (Gout) - Pipeline by Immune Response BioPharma, Inc., H2 2016
Gouty Arthritis (Gout) - Pipeline by IOmet Pharma, H2 2016
Gouty Arthritis (Gout) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
Gouty Arthritis (Gout) - Pipeline by LG Life Science LTD., H2 2016
Gouty Arthritis (Gout) - Pipeline by Monosol Rx LLC, H2 2016
Gouty Arthritis (Gout) - Pipeline by Nimbus Therapeutics, LLC, H2 2016
Gouty Arthritis (Gout) - Pipeline by Opsona Therapeutics Limited, H2 2016
Gouty Arthritis (Gout) - Pipeline by Polaris Pharmaceuticals, Inc., H2 2016
Gouty Arthritis (Gout) - Pipeline by ProteoThera, Inc., H2 2016
Gouty Arthritis (Gout) - Pipeline by Selvita S.A., H2 2016
Gouty Arthritis (Gout) - Pipeline by Swedish Orphan Biovitrum AB, H2 2016
Gouty Arthritis (Gout) - Pipeline by Teijin Pharma Limited, H2 2016
Gouty Arthritis (Gout) - Pipeline by TWi Pharmaceuticals, Inc., H2 2016
Gouty Arthritis (Gout) - Pipeline by Wellstat Therapeutics Corporation, H2 2016
Gouty Arthritis (Gout) - Pipeline by XL-protein GmbH, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Gouty Arthritis (Gout) - Dormant Projects, H2 2016
Gouty Arthritis (Gout) - Dormant Projects (Contd..1), H2 2016
Gouty Arthritis (Gout) - Dormant Projects (Contd..2), H2 2016
Gouty Arthritis (Gout) - Discontinued Products, H2 2016 93

LIST OF FIGURES

Number of Products under Development for Gouty Arthritis (Gout), H2 2016
Number of Products under Development for Gouty Arthritis (Gout) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Gouty Arthritis (Gout) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: